Background {#Sec1}
==========

Congenital Hyperinsulinism (CHI) is an important cause of severe hypoglycaemia in infancy due to excessive, dysregulated insulin secretion \[[@CR1]\]. In CHI, the most common genetic aetiology is a mutation in one of the potassium ATP (K~ATP~) channel genes, *ABCC8* or *KCNJ11*. This channel links glucose metabolism to insulin release in the pancreatic beta-cell. Recessive K~ATP~ mutations in the homozygous or compound heterozygous state cause diffuse CHI, in which beta-cells throughout the entire pancreas are abnormal and hypersecrete insulin \[[@CR2]\]. Diffuse CHI due to K~ATP~ mutations is typically unresponsive to medication, requiring subtotal pancreatectomy to achieve normoglycaemia.

In focal CHI, another form of CHI that is also generally medication-unresponsive, only a small region of the pancreas is affected by pathology \[[@CR1]\]. The focal lesion occurs due to a paternally inherited mutation in *ABCC8* or *KCNJ11* combined with post-zygotic loss of maternal heterozygosity within the affected tissue. The latter causes clonal expansion of endocrine rich tissue due to the loss of cell cycle repressor genes that are expressed from the maternal allele \[[@CR2]\]. Excess insulin results from the clonally expanded, abnormal beta-cells expressing the mutated ATP-sensitive potassium channel. Focal CHI can be cured by limited resection, compared with more extensive pancreatectomy, which is associated with significant risk of lifelong diabetes and exocrine insufficiency.

Distinguishing focal CHI from other forms is therefore critical, and its diagnosis is based on a crucial combination of compatible genetics (i.e. paternal mutation in *KCNJ11* or *ABCC8*) and 6-(18F)Fluoro-L-3,4-dihydroxyphenylalanine (^18^F-DOPA) positron emission tomography (PET)/CT imaging which localises the lesion \[[@CR1], [@CR2]\]. Uptake of ^18^F-DOPA by pancreatic beta-cells occurs due to expression of aromatic amine decarboxylase (AADC), resulting in conversion of L-DOPA to dopamine and sequestration of the radiotracer within the beta-cells \[[@CR3], [@CR4]\]. Focal lesions are distinguishable from the remainder of the pancreas due to uptake and sustained retention of the radiotracer by the hyperplastic, clonally-expanded beta-cells within the lesion, in contrast to the rest of the pancreas \[[@CR4]\]. The mechanism for this remains unclear.

^18^F-DOPA PET/CT represents a significant advance over the invasive and technically challenging technique of pancreatic arterial calcium stimulation with hepatic venous sampling previously used to identify focal lesions \[[@CR4]\]. However, while this modality remains the investigation of choice to non-invasively identify a focal CHI lesion prior to surgery, with greater experience, it has been found to be less sensitive in detecting focal lesions than originally reported \[[@CR5], [@CR6]\]. We report a case in which a paternally inherited *KCNJ11* mutation was associated with diffuse ^18^F-DOPA uptake but later confirmed to have focal CHI at the time of surgery.

Case presentation {#Sec2}
=================

A male infant was born at 39 weeks' gestation with a birth weight of 4.34 kg (98--99.6th percentile) after an uncomplicated pregnancy and normal delivery. Profound hypoglycaemia was noted with poor feeding and irritability in the early neonatal period. He required an elevated glucose infusion rate of 15.4 mg/kg/min to achieve normoglycaemia. Consistent with this, CHI was confirmed with raised insulin and c-peptide at the time of hypoglycaemia (glucose 1.8 mmol/L, insulin 140 pmol/L, c-peptide 741 pmol/L). There were no dysmorphic features or other medical problems to suggest a syndromic aetiology. He was unresponsive to medical therapy with persistent need for high dextrose infusion despite maximum doses of diazoxide and octreotide, the mainstays of medical treatment, which act by inhibiting insulin release.

Genetic testing revealed a paternally inherited mutation in *KCNJ11*, c.286G \> A (p.Ala96Thr), suggesting the presence of focal CHI. This mutation has previously been described as recessive and a cause for focal CHI in another patient \[[@CR7]\]. However, ^18^F-DOPA PET/CT scanning demonstrated diffuse uptake throughout the entire pancreas (Fig. [1](#Fig1){ref-type="fig"}A-C). Both ordered subset expectation maximization (OSEM) and ultra-high definition (UHD) reconstruction were performed on the PET images and standardised uptake values (SUV) measurements were obtained at each time point (5--15 min, 15--30 min, 30--45 min, 45--60 min and 60--80 min) at the following sites: pancreatic head, body, tail, and region of most avid uptake (Table [1](#Tab1){ref-type="table"}). In addition, maximum intensity projection (MIP) images were visually inspected for localised increased radiotracer concentrations, but there was no obvious localisation of a focal lesion. Fig. 1^18^F-DOPA PET/CT Pancreatic Imaging. ^18^F-DOPA PET/CT imaging in the case described demonstrates diffuse pancreatic uptake (**a**-**c**). A coronal maximal intensity projection (MIP) image with OSEM reconstruction is shown at 30--45 min after radionucleotide injection (**a**) with merged coronal (**b**) and axial (**c**) PET and CT images. The previous patient with the same *KCNJ11* mutation \[[@CR7]\] demonstrated similar findings on ^18^F-DOPA PET-CT scanning with diffuse uptake throughout the pancreas at 44 min post-injection on both MIP and merged PET-CT coronal images (**d**, **e**)Table 1SUV from both OSEM and UHD reconstruction of the ^18^F-DOPA PET Imaging shown up to a post injection duration of 60 minReconstruction FormatTime Post^ 18^F-DOPA Administration (mins)5--1515--3030--4545--60Region of most avid uptakeOESM6.06.86.76.9UHD9.210.910.410.7HeadOESM6.76.56.56.5UHD9.29.89.39.2BodyOESM6.76.66.66.0UHD9.89.48.78.5TailOESM5.75.86.15.9UHD8.49.09.68.5MeanOESM6.36.36.46.1UHD9.19.49.28.7

The uptake was quantified by calculating SUV ratios for the area of most avid intake, which was in the proximal body, at 45--60 min (Table [1](#Tab1){ref-type="table"}). The maximum SUV value was normalized to the mean of the entire pancreas for both OESM and UHD reconstruction, giving ratios of 6.9/6.1 = 1.1 and 10.7/8.7 = 1.2 respectively, whereas a ratio of \> 1.5 is generally considered predictive of focal disease.

The authors of the previous patient with the same *KCNJ11* mutation and focal CHI were contacted to share their experience to guide clinical management \[[@CR7]\]. Similar scan findings to our case were noted (Fig. [1](#Fig1){ref-type="fig"}D-E). As this previous child's condition had been unstable with no response to medical therapy, surgery had been performed and a focal lesion was identified. Hypoglycaemia resolved after surgery.

Given this outcome, the decision was made to proceed to pancreatic biopsy, leading to the identification of a 4.9 mm by 1.7 mm lesion at the pancreatic neck. The histology demonstrated islands of endocrine cells, predominantly insulin and proinsulin positive, interspersed by bands of fibrous tissue and some acinar cells, consistent with a focal lesion (Fig. [2](#Fig2){ref-type="fig"}). Additional biopsy of the pancreatic tail showed normal pancreatic tissue without evidence of hyperplasia. After resection of the focal lesion, hypoglycaemia resolved and the patient was able to maintain an age-appropriate duration of fasting on regular feeds. Fig. 2Focal CHI Lesion Histology. (**a**) Haematoxylin & eosin and (**b**) insulin staining of the resected pancreas revealed a 4.9 × 1.7 mm nodular lesion consistent with the presence of a focal lesion. Size marker is equivalent to 0.5 mm

Discussion and conclusions {#Sec3}
==========================

We describe the case of patient with focal CHI and discordant genetic and imaging findings. Although the patient possessed a paternally inherited K~ATP~ mutation, diffuse uptake was seen on ^18^F-DOPA PET/CT scan and ultimately, pancreatic biopsy was required to identify and confirm the focal lesion.

While the inheritance of a recessive paternal K~ATP~ mutation is a key feature in the diagnosis of focal CHI, the presence of pancreatic loss of heterozygosity and histologic confirmation of a focal lesion cannot be determined without biopsy of the tissue. While ^18^F-DOPA PET/CT is used to identify and localise focal CHI lesions prior to surgery \[[@CR1], [@CR2]\], it is important to recognise the possibility of discordant outcomes, as demonstrated by this case.

The reason for under-detection of focal lesions is unclear. Given the postulated mechanism of AADC beta-cell expression, and sequestration of L-DOPA following conversion to dopamine, localised tracer uptake by the clonally-expanded beta-cells would be expected to occur for all focal lesions. One potential mechanism may be related to lesion size \[[@CR6]\]. False negative results have been attributed to both large and small focal lesions, with the smallest reported lesion detected by ^18^F-DOPA PET/CT being 5 × 4 mm \[[@CR6], [@CR8]\]. It is possible that the lesion in our patient was too small at 4.9.× 1.7 mm for detection. Of note, this lesion is one of the smallest lesions identified at our centre.

Similar discordance in imaging findings have been observed in a separate case with the same mutation \[[@CR7]\]. This raises the possibility of a mutation specific imaging outcome, although without a mechanistic explanation. Alternatively, the findings could be purely coincidental. Regardless, this case highlights the need for intra-operative pancreatic biopsy if focal CHI is strongly suspected but ^18^F-DOPA PET/CT scanning fails to identify a well delineated focal lesion. Our case reinforces the importance of pancreatic biopsy in order to avoid unnecessary extensive pancreatectomy in focal CHI and the attendant future risks of diabetes and exocrine insufficiency.
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